title: The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.
abstract: The CARIATIDE study was designed to assess the impact of educational materials (EMs) on compliance and persistence rates with aromatase inhibitor (AI) treatment in postmenopausal women with hormone-receptor-positive early breast cancer. Patients were randomized to standard AI treatment (Group A; N = 1379) or standard AI treatment plus EMs containing information on a range of breast-cancer-related topics (Group B; N = 1379). Standardized questionnaires assessed investigator-perceived levels of care and evaluated patient compliance and behavior. At 1 year, there was no significant difference in compliance between Group A and Group B (81% vs. 82%, p = 0.4524). However, higher compliance in patients receiving EMs was observed in Sweden/Finland (p = 0.0246). Compliance with initial AI and persistence rate were not significantly altered by EM. Other factors associated with improved compliance, irrespective of EMs, e.g. administration of chemotherapy were identified.
authors.affiliation: Multidisciplinary Breast Centre and Gynaecological Oncology, UZ Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
authors.forename: Patrick
authors.initials: P
authors.lastname: Neven
authors.affiliation: Breast Unit, Athens University Medical School and Department of Surgery, Athens, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Markopoulos
authors.affiliation: Department of Oncology, Tampere University Hospital, Tampere, Finland.
authors.forename: Minna
authors.initials: M
authors.lastname: Tanner
authors.affiliation: Hôpital St Louis, Paris, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Marty
authors.affiliation: Universitäts-Frauenklinik Ulm, Ulm, Germany.
authors.forename: Rolf
authors.initials: R
authors.lastname: Kreienberg
authors.affiliation: University College London, London, UK.
authors.forename: Louise
authors.initials: L
authors.lastname: Atkins
authors.affiliation: International Drug Development Institute, Ottignies-Louvain-la-Neuve, Belgium.
authors.forename: Ann
authors.initials: A
authors.lastname: Franquet
authors.affiliation: Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.affiliation: Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
authors.forename: Silvia
authors.initials: S
authors.lastname: Neciosup
authors.affiliation: Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic.
authors.forename: Petra
authors.initials: P
authors.lastname: Tesarova
authors.affiliation: Oncologia Medica, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Barni
authors.affiliation: AstraZeneca, Brussels, Belgium.
authors.forename: Veronique
authors.initials: V
authors.lastname: Deschamp
mesh_terms: D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D000077289:Letrozole; D008197:Lymph Node Excision; D008408:Mastectomy; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D010353:Patient Education as Topic / Q000379:methods*; D017698:Postmenopause; D014230:Triazoles / Q000627:therapeutic use*; D016903:Drug Monitoring
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D000077289:Letrozole
keywords: Adherence; Breast cancer; Compliance; Endocrine therapy; Oncology; Persistence